Compounds > metformin
Page last updated: 2024-10-30

metformin and 2019 Novel Coronavirus Disease

metformin has been researched along with 2019 Novel Coronavirus Disease in 112 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
" We conducted a Phase II double-blind placebo-controlled trial that aimed to determine the impact of metformin on blood glucose levels among people with prediabetes (defined as impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT]) and HIV in SSA."9.69Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial. ( Alam, U; Bates, K; Charles, G; Garrib, A; Jaffar, S; Kivuyo, S; Luo, H; Majaliwa, E; Mfinanga, S; Nyirenda, MJ; Ramaiya, K; Simbauranga, R; van Widenfelt, E; Wang, D, 2023)
"Multiple observational studies have associated metformin prescription with reduced progression of abdominal aortic aneurysm (AAA)."9.41Protocol for the Metformin Aneurysm Trial (MAT): a placebo-controlled randomised trial testing whether metformin reduces the risk of serious complications of abdominal aortic aneurysm. ( Arnott, C; Bown, M; Golledge, J; Jones, G; Li, Q; Monaghan, H; Morris, D; Moxon, J; Neal, B; Norman, R; Roake, J, 2021)
"This observational, retrospective study utilized EHR data from 52 hospitals for COVID-19 patients with PCOS or prediabetes treated with metformin or levothyroxine/ondansetron (controls)."8.12Metformin is associated with reduced COVID-19 severity in patients with prediabetes. ( Antony, B; Blau, H; Bramante, C; Casiraghi, E; Chan, LE; Coleman, B; Gargano, M; Haendel, M; Harris, NL; Laraway, B; Reese, J; Robinson, PN; Sahner, D; Valentini, G; Wilkins, K; Zaman, A, 2022)
"Metformin-associated lactic acidosis (MALA) is an extremely rare but life-threatening adverse effect of metformin treatment."8.12Metformin-associated Lactic Acidosis with Hypoglycemia during the COVID-19 Pandemic. ( Hazama, Y; Irie, Y; Kosugi, M; Maruo, Y; Obata, Y; Takayama, K; Yamaguchi, H; Yasuda, T, 2022)
" Here, we present a case of a diabetic patient with acute kidney injury, metformin-associated lactic acidosis, and COVID-19."8.02Metformin-associated lactic acidosis and acute kidney injury in the era of COVID-19. ( Kalaitzidis, RG; Koukoulaki, M; Theofilis, P; Vlachopanos, G; Vordoni, A, 2021)
"Metformin pretreatment before anesthesia enhanced cognitive performance in the novel object test."5.72Metformin alleviates prolonged isoflurane inhalation induced cognitive decline via reducing neuroinflammation in adult mice. ( Fang, X; Gu, X; Liu, S; Peng, L; Xia, T; Xie, W; Xu, J, 2022)
" We conducted a Phase II double-blind placebo-controlled trial that aimed to determine the impact of metformin on blood glucose levels among people with prediabetes (defined as impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT]) and HIV in SSA."5.69Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial. ( Alam, U; Bates, K; Charles, G; Garrib, A; Jaffar, S; Kivuyo, S; Luo, H; Majaliwa, E; Mfinanga, S; Nyirenda, MJ; Ramaiya, K; Simbauranga, R; van Widenfelt, E; Wang, D, 2023)
"Metformin decreased cervical tumor hypoxia in this trial that selected for patients with hypoxic tumor."5.51A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer. ( Bruce, J; Cairns, R; Chaudary, N; Croke, J; D'Souza, D; Dhani, N; Fyles, A; Han, K; Jaffray, D; Koritzinsky, M; Lee, TY; Metser, U; Milosevic, M; Pakbaz, S; Pintilie, M; Rouzbahman, M; Shek, T; Vines, D, 2022)
"Multiple observational studies have associated metformin prescription with reduced progression of abdominal aortic aneurysm (AAA)."5.41Protocol for the Metformin Aneurysm Trial (MAT): a placebo-controlled randomised trial testing whether metformin reduces the risk of serious complications of abdominal aortic aneurysm. ( Arnott, C; Bown, M; Golledge, J; Jones, G; Li, Q; Monaghan, H; Morris, D; Moxon, J; Neal, B; Norman, R; Roake, J, 2021)
"To investigate the effects of COVID-19 infection in DM patients, we reviewed literature from Google Scholar search engine and PubMed database from '2013 to 2020' using the terms "COVID-19; SARS-CoV-2; Diabetes mellitus; obesity; Angiotensin-converting enzyme 2; ACE2; Insulin and Metformin."5.22Diabetes mellitus and COVID-19: review of a lethal interaction from the cellular and molecular level to the bedside. ( Ali Kazem, T; Filayih Hassan, A; Paridar, P; Pezeshki, SMS; Pezeshki, SP; Zeylabi, F, 2022)
" Metformin and SGLT2 inhibitors should be discontinued in patients with severe forms of COVID-19 owing to the risks of lactic acidosis and ketoacidosis."5.05COVID-19 in diabetic patients: Related risks and specifics of management. ( Hermans, MP; Maiter, D; Orioli, L; Thissen, JP; Vandeleene, B; Yombi, JC, 2020)
" We tested the drugs metformin (AMPK activator) and baicalin (CPT1A activator) in different experimental models mimicking COVID-19 associated inflammation in lung and kidney."4.31Enhanced fatty acid oxidation through metformin and baicalin as therapy for COVID-19 and associated inflammatory states in lung and kidney. ( Alcalde-Estévez, E; Castillo, C; Castro, A; Costa, IG; Fernández, L; Herrero, JI; Jansen, J; Kramann, R; Lamas, S; Miguel, V; Nagai, J; Ranz, I; Reimer, KC; Rey-Serra, C; Rodríguez González-Moro, JM; Sancho, D; Sevilla, L; Sirera, B; Tituaña, J, 2023)
" We sought to determine the effect of metformin, dipeptidyl peptidase-4 inhibitors (DPP-4i), and insulin on admission to the intensive care unit (ICU), need for assisted ventilation, development of renal insufficiency, and mortality in patients admitted with COVID-19 infection after controlling for clinical variables and other relevant diabetes-related medications in patients with type 2 diabetes mellitus (DM)."4.31Association of Metformin, Dipeptidyl Dipeptidase-4 Inhibitors, and Insulin with Coronavirus Disease 2019-Related Hospital Outcomes in Patients with Type 2 Diabetes. ( Alwakeel, M; Bena, J; Buehler, L; Lansang, MC; Makin, V; Obiri-Yeboah, D; Pantalone, KM; Zhou, K, 2023)
"Metformin-associated lactic acidosis (MALA) is an extremely rare but life-threatening adverse effect of metformin treatment."4.12Metformin-associated Lactic Acidosis with Hypoglycemia during the COVID-19 Pandemic. ( Hazama, Y; Irie, Y; Kosugi, M; Maruo, Y; Obata, Y; Takayama, K; Yamaguchi, H; Yasuda, T, 2022)
"This observational, retrospective study utilized EHR data from 52 hospitals for COVID-19 patients with PCOS or prediabetes treated with metformin or levothyroxine/ondansetron (controls)."4.12Metformin is associated with reduced COVID-19 severity in patients with prediabetes. ( Antony, B; Blau, H; Bramante, C; Casiraghi, E; Chan, LE; Coleman, B; Gargano, M; Haendel, M; Harris, NL; Laraway, B; Reese, J; Robinson, PN; Sahner, D; Valentini, G; Wilkins, K; Zaman, A, 2022)
" Here, we present a case of a diabetic patient with acute kidney injury, metformin-associated lactic acidosis, and COVID-19."4.02Metformin-associated lactic acidosis and acute kidney injury in the era of COVID-19. ( Kalaitzidis, RG; Koukoulaki, M; Theofilis, P; Vlachopanos, G; Vordoni, A, 2021)
"Acute respiratory distress syndrome (ARDS), an inflammatory condition with high mortality rates, is common in severe COVID-19, whose risk is reduced by metformin rather than other anti-diabetic medications."4.02Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. ( Aleman-Muench, GR; Arditi, M; Chen, W; Crother, TR; de la Torre, JC; Gatchalian, R; Kang, S; Karin, M; Lewis, G; Lipton, SA; Liu, Y; Luevanos, M; Rundberg Nilsson, A; Sanchez-Lopez, E; Soroosh, P; Teijaro, J; Tourtellotte, WG; Trudler, D; Xian, H; Zhang, Y, 2021)
"Metformin was significantly associated with reduced mortality in women with obesity or type 2 diabetes who were admitted to hospital for COVID-19."4.02Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. ( Abdelwahab, N; Benson, B; Bramante, CT; Feng, R; Gronski, J; Guzman, G; Hovertsen, S; Ingraham, NE; King, S; Marmor, S; McNeil, C; Meehan, T; Murray, TA; Pendleton, KM; Tamariz, L; Tignanelli, CJ; Vojta, D, 2021)
"Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people."3.30Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. ( Anderson, BJ; Beckman, KB; Belani, HK; Bhat, NS; Boulware, DR; Bramante, CT; Buse, JB; Cohen, K; Erickson, SM; Fenno, SL; Griffiths, G; Hartman, KM; Huling, JD; Karger, AB; Klatt, NR; Liebovitz, DM; Lindberg, SM; Mehta, T; Murray, TA; Nicklas, JM; Odde, DJ; Patel, B; Proper, JL; Pullen, M; Puskarich, MA; Rose, MR; Sherwood, NE; Siegel, LK; Thompson, JL; Tignanelli, CJ; Wirtz, EL, 2023)
"The primary composite end point was hypoxemia (≤93% oxygen saturation on home oximetry), emergency department visit, hospitalization, or death."3.11Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. ( Anderson, B; Avula, N; Belani, HK; Biros, M; Boulware, DR; Bramante, CT; Buse, JB; Cohen, K; Erickson, SM; Fenno, SL; Fricton, R; Hagen, AA; Hartman, KM; Huling, JD; Ingraham, NE; Karger, AB; Klatt, NR; Lee, S; Liebovitz, DM; Lindberg, S; Luke, DG; Murray, TA; Nicklas, JM; Odde, DJ; Patel, B; Proper, JL; Pullen, MF; Puskarich, MA; Rao, V; Reddy, NV; Saveraid, HG; Sherwood, NE; Siegel, LK; Thompson, JL; Tignanelli, CJ; Tordsen, WJ; Zaman, A, 2022)
"Metformin has been used as an oral anti-hyperglycaemic drug since the late 1950s; however, following the release in 1998 of the findings of the 20-year United Kingdom Prospective Diabetes Study (UKPDS), metformin use rapidly increased and today is the first-choice anti-hyperglycaemic drug for patients with type 2 diabetes (T2D)."3.01Repurposing Metformin for Vascular Disease. ( Anderson, TJ; Ding, H; Hill, MA; Hollenberg, MD; Marei, I; Triggle, CR; Ye, K, 2023)
" The heterogeneity across the studies, baseline characteristics of the included patients, shortage of dosage and the duration of antidiabetic drugs and autonomy of drug selection might limit the objectivity and accuracy of results."3.01Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. ( Fang, X; Jia, H; Lin, H; Ma, X; Qi, L; Wang, L; Weng, L; Zhan, K, 2023)
"Metformin is a biguanide, evolved as one of the most widely used medicines."3.01Metformin: new applications for an old drug. ( Daneshvar, S; Gholipour-Khalili, E; Hamzehzadeh, S; Hosseini, MS; Majidazar, R; Naseri, A; Rezazadeh-Gavgani, E; Sanaie, S; Seraji, P; Seyedi-Sahebari, S, 2023)
"Individuals with obesity are known to have increased inflammation, increased risk to select autoimmune diseases, impaired response to several infections, and impaired vaccine response."2.82Targeting T cell (oxidative) metabolism to improve immunity to viral infection in the context of obesity. ( Greene, E; MacIver, NJ, 2022)
"Management of hyperinsulinemia by pharmacological approaches, including metformin, sodium-glucose cotransporter 2 inhibitor, or β3-adrenergic receptor agonist, decreased GRP78 gene expression in adipose tissue."2.72Possible Involvement of Adipose Tissue in Patients With Older Age, Obesity, and Diabetes With SARS-CoV-2 Infection (COVID-19) via GRP78 (BIP/HSPA5): Significance of Hyperinsulinemia Management in COVID-19. ( Fukuhara, A; Kita, S; Nishitani, S; Otsuki, M; Shimomura, I; Shin, J; Toyoda, S, 2021)
"Metformin has been shown to significantly correlate with lower mortality in obese or type 2 diabetic women hospitalized for COVID-19."2.72Metformin - a new approach. ( Cwynar-Zając, Ł, 2021)
"Metformin was extensively studied for its antioxidant, anti-inflammatory, immunomodulatory, and antiviral capabilities that would explain its ability to confer cardiopulmonary and vascular protection in COVID-19."2.72Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing. ( Büsselberg, D; Kubatka, P; Liskova, A; Samuel, SM; Varghese, E, 2021)
"Metformin is an established insulin receptor sensitising antihyperglycemic agent, is highly affordable, and has superior safety and efficacy profiles."2.72Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications. ( Driver, C; Gcwensa, SK; Mbara, KC; Mcobothi, EN; Mkhombo, NT; Mofo Mato, PE; Nzuza, S; Owira, PM, 2021)
"Metformin is an anti-hyperglycemic agent with host-directed immune-modulatory effects, which relieve exaggerated inflammation and reduce lung tissue damage."2.72The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review. ( Hajikhani, B; Mirsaeidi, M; Nasiri, MJ; Nejadghaderi, SA; Zahmatkesh, MM; Zangiabadian, M, 2021)
"Inflammation is implicated in the development and severity of the coronavirus disease 2019 (COVID-19), as well as in the pathophysiology of diabetes."2.66Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era? ( Ferrannini, E; Katsiki, N, 2020)
"The pandemic of coronavirus disease 2019 (COVID-19), a disease which causes severe lung injury and multiple organ damage, presents an urgent need for new drugs."2.66Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury. ( Chen, X; Deng, Q; Guo, H; Leng, Q; Qiu, L; Zhang, C, 2020)
" Based on these results, a clinical drug-drug interaction study to evaluate the effect of ensitrelvir on the pharmacokinetics of P-gp, BCRP, OATP1B1, OATP1B3, and OCT1 substrates was conducted with a cocktail approach using digoxin (P-gp substrate), rosuvastatin (BCRP, OATP1B1, and OATP1B3 substrate), and metformin (OCT1 substrate)."1.91Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies. ( Fukuhara, T; Kubota, R; Kuwata, A; Matsuo, Y; Matsuzaki, T; Oka, R; Shimizu, R; Sonoyama, T, 2023)
"The global pandemic of coronavirus disease 2019 (COVID-19) continues to affect people around the world, with one of the most frequent comorbidities being Type 2 Diabetes (T2D)."1.91Gut microbiota in patients with COVID-19 and type 2 diabetes: A culture-based method. ( Kamyshnyi, A; Kobyliak, N; Petakh, P, 2023)
"The effect of type 2 diabetes, metformin, and insulin on COVID-19 were analyzed, respectively."1.72Effects of Metformin, Insulin on Hematological Parameters of COVID-19 Patients with Type 2 Diabetes. ( Griga, V; Kamyshnyiy, A; Loshak, K; Mohammed, IB; Petakh, P; Poliak, I, 2022)
"Metformin pretreatment before anesthesia enhanced cognitive performance in the novel object test."1.72Metformin alleviates prolonged isoflurane inhalation induced cognitive decline via reducing neuroinflammation in adult mice. ( Fang, X; Gu, X; Liu, S; Peng, L; Xia, T; Xie, W; Xu, J, 2022)
"Metformin use was associated with lower mortality and lower odds for hyperinflammatory syndrome."1.72Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort. ( Au, ICH; Chung, MSH; Cowling, BJ; Kwok, ACY; Lau, EHY; Lau, KTK; Low, MCH; Lui, AYC; Lui, DTW; Wong, CKH; Xiong, X, 2022)
"Five of the patients had pre-existing type 2 diabetes mellitus (DM)."1.72COVID-19 and diabetic ketoacidosis: A case series at an urban district hospital in South Africa. ( Dicks, HN; Naidoo, K, 2022)
"A total of 4462 patients with Type 2 diabetes and confirmed COVID-19 were identified."1.72Metformin use and mortality and length of stay among hospitalized patients with type 2 diabetes and COVID-19: A multiracial, multiethnic, urban observational study. ( George, CJ; Lin, J; Liu, J; Miao, E; Yoo, D; Zhang, K, 2022)
"Adults with type 2 diabetes patients and a current prescription for metformin and other glucose-lowering agents (MF+) were compared to those with a current prescription for glucose-lowering agents that did not include metformin (MF-)."1.62Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes. ( Acosta-Mena, D; Adderley, NJ; Anand, A; Bangash, MN; Byne, N; Chandan, JS; Cooper, JM; Dhalla, S; Ghosh, S; Gokhale, K; Hanif, W; Haroon, S; Jackson, T; Khunti, K; Narendran, P; Nirantharakumar, K; Okoth, K; Sainsbury, C; Subramanian, A; Surenthirakumaran, R; Tahrani, AA; Taverner, T; Thomas, GN; Toulis, KA; Wang, J; Zemedikun, D, 2021)
"Metformin users were defined as those who had been prescribed continuous oral metformin for over a period of ≥ 90 days, and the control group was defined as all other patients."1.62Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study. ( Oh, TK; Song, IA, 2021)
"To evaluate the impact of type 2 diabetes (T2D) and obesity on COVID-19 severity, we conducted a cohort study with 28,095 anonymized COVID-19 patients using data from the COVID-19 Research Database from January 1, 2020 to November 30, 2020."1.62Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States. ( Ando, W; Atsuda, K; Hanaki, H; Horii, T; Otori, K; Uematsu, T, 2021)
"Both obesity and type 2 diabetes (T2D) are recognized risk factors for developing a more severe form of COVID-19, with a higher death rate."1.62[Continuing or stopping metformin in patients with type 2 diabetes exposed to SARS-CoV-2 ?] ( Paquot, N; Scheen, AJ, 2021)
"Type 2 diabetes is considered to be one of the essential risks of adverse outcomes in coronavirus disease 2019 (COVID-19)."1.62Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study. ( Chen, W; Chen, Y; Cheng, X; Duan, P; Gong, Y; Li, C; Li, F; Li, L; Li, W; Xin, S; Zhou, B; Zhou, X, 2021)
"Of 328 patients with COVID-19 and type 2 diabetes included in the study cohort, 30."1.62Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study. ( Chen, Z; Gong, Y; Jiang, N; Li, H; Liu, L; Lu, Z; Tan, X; Tian, M; Wang, J; Xiong, N; Yang, H; Yin, X, 2021)
"Although type 2 diabetes mellitus (T2DM) has been reported as a risk factor for coronavirus disease 2019 (COVID-19), the effect of pharmacologic agents used to treat T2DM, such as metformin, on COVID-19 outcomes remains unclear."1.56Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19. ( Gongol, B; He, M; Hepokoski, M; Jiang, W; Li, J; Li, WX; Liu, J; Malhotra, A; Marin, T; McCowen, KC; Shyy, JY; Thomas, RL; Wei, Q; Xiong, N; Xiong, W; Yuan, JX, 2020)
"Hydroxychloroquine was recently promoted in patients infected with COVID-19 infection."1.56A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study. ( Montastruc, JL; Toutain, PL, 2020)
"We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine's registry of COVID-19 patients (SEMI-COVID-19 Registry)."1.56Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. ( Acedo, IEA; Ayala-Gutiérrez, MM; Canteli, SP; Cosío, SF; Ena, J; Ferrer, RG; Fuentes-Jiménez, F; Garcia, MG; Gómez-Huelgas, R; Jorge Huerta, L; Lecumberri, JJN; López-Carmona, MD; Madrazo, M; Martínez, FA; Montes, BV; Muñoz, JA; Pérez, CM; Pérez-Belmonte, LM; Pérez-Martínez, P; Ramos-Rincón, JM; Ripper, CJ; Rodríguez, BC; Rubio-Rivas, M; Sola, JF; Torres-Peña, JD, 2020)
"Metformin has been shown to be effective in HDT and can assist in the treatment of the viral and bacterial infectious disease."1.56[Metformin: one of the possible options to reduce the mortality of severe coronavirus disease 2019?] ( Han, R; He, Y; Pan, Y, 2020)

Research

Studies (112)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's112 (100.00)2.80

Authors

AuthorsStudies
Gordon, DE1
Jang, GM1
Bouhaddou, M1
Xu, J2
Obernier, K1
White, KM1
O'Meara, MJ1
Rezelj, VV1
Guo, JZ1
Swaney, DL1
Tummino, TA1
Hüttenhain, R1
Kaake, RM1
Richards, AL1
Tutuncuoglu, B1
Foussard, H1
Batra, J1
Haas, K1
Modak, M1
Kim, M1
Haas, P1
Polacco, BJ1
Braberg, H1
Fabius, JM1
Eckhardt, M1
Soucheray, M1
Bennett, MJ1
Cakir, M1
McGregor, MJ1
Li, Q3
Meyer, B1
Roesch, F1
Vallet, T1
Mac Kain, A1
Miorin, L1
Moreno, E1
Naing, ZZC1
Zhou, Y1
Peng, S1
Shi, Y2
Zhang, Z1
Shen, W1
Kirby, IT1
Melnyk, JE1
Chorba, JS1
Lou, K1
Dai, SA1
Barrio-Hernandez, I1
Memon, D1
Hernandez-Armenta, C1
Lyu, J1
Mathy, CJP1
Perica, T1
Pilla, KB1
Ganesan, SJ1
Saltzberg, DJ1
Rakesh, R1
Liu, X2
Rosenthal, SB1
Calviello, L1
Venkataramanan, S1
Liboy-Lugo, J1
Lin, Y1
Huang, XP1
Liu, Y6
Wankowicz, SA1
Bohn, M1
Safari, M1
Ugur, FS1
Koh, C1
Savar, NS1
Tran, QD1
Shengjuler, D1
Fletcher, SJ1
O'Neal, MC1
Cai, Y2
Chang, JCJ1
Broadhurst, DJ1
Klippsten, S1
Sharp, PP1
Wenzell, NA1
Kuzuoglu-Ozturk, D1
Wang, HY1
Trenker, R1
Young, JM1
Cavero, DA1
Hiatt, J1
Roth, TL1
Rathore, U1
Subramanian, A2
Noack, J1
Hubert, M1
Stroud, RM1
Frankel, AD1
Rosenberg, OS1
Verba, KA1
Agard, DA1
Ott, M1
Emerman, M1
Jura, N1
von Zastrow, M1
Verdin, E1
Ashworth, A1
Schwartz, O1
d'Enfert, C1
Mukherjee, S2
Jacobson, M1
Malik, HS1
Fujimori, DG1
Ideker, T1
Craik, CS1
Floor, SN1
Fraser, JS1
Gross, JD1
Sali, A1
Roth, BL1
Ruggero, D1
Taunton, J1
Kortemme, T1
Beltrao, P1
Vignuzzi, M1
García-Sastre, A1
Shokat, KM1
Shoichet, BK1
Krogan, NJ1
Ando, W1
Horii, T1
Uematsu, T1
Hanaki, H1
Atsuda, K1
Otori, K1
Cwynar-Zając, Ł1
Li, J9
Wei, Q3
McCowen, KC2
Xiong, W2
Liu, J5
Jiang, W2
Thomas, RL2
Hepokoski, M2
He, M2
Shyy, JYJ1
Malhotra, A2
Xiong, N3
Li, WX2
Shin, J1
Toyoda, S1
Nishitani, S1
Fukuhara, A1
Kita, S1
Otsuki, M1
Shimomura, I1
Kamyshnyi, O1
Matskevych, V1
Lenchuk, T1
Strilbytska, O1
Storey, K1
Lushchak, O1
Albini, A1
Calabrone, L1
Carlini, V1
Benedetto, N1
Lombardo, M1
Bruno, A1
Noonan, DM1
Luk, AOY1
Yip, TCF1
Zhang, X6
Kong, APS1
Wong, VW1
Ma, RCW1
Wong, GL1
Ali Kazem, T1
Zeylabi, F1
Filayih Hassan, A1
Paridar, P1
Pezeshki, SP1
Pezeshki, SMS1
Cory, TJ1
Emmons, RS1
Yarbro, JR1
Davis, KL1
Pence, BD1
Vordoni, A1
Theofilis, P1
Vlachopanos, G1
Koukoulaki, M1
Kalaitzidis, RG1
Golledge, J1
Arnott, C1
Moxon, J1
Monaghan, H1
Norman, R1
Morris, D1
Jones, G1
Roake, J1
Bown, M1
Neal, B1
Bakhtiari, M1
Asadipooya, K1
Kow, CS4
Ramachandram, DS1
Hasan, SS4
Ojeda-Fernández, L1
Foresta, A1
Macaluso, G1
Colacioppo, P1
Tettamanti, M1
Zambon, A1
Genovese, S1
Fortino, I1
Leoni, O1
Roncaglioni, MC1
Baviera, M1
Usman, A1
Bliden, KP1
Cho, A1
Walia, N1
Jerjian, C1
Singh, A2
Kundan, P1
Duhan, S1
Tantry, US1
Gurbel, PA1
Kumar, S1
Raja, R1
Wong, CKH1
Lui, DTW2
Lui, AYC1
Low, MCH1
Kwok, ACY1
Lau, KTK1
Au, ICH1
Xiong, X1
Chung, MSH1
Lau, EHY1
Cowling, BJ1
Al-Salameh, A4
Wiernsperger, N3
Cariou, B3
Lalau, JD3
Espinosa-Rodriguez, BA1
Nieto-Moreno, AM1
Gonzalez Llerena, JL1
Rico-Torres, TA1
Carranza-Rosales, P1
Mendez-Lopez, LF1
Balderas-Renteria, I1
Takayama, K1
Obata, Y1
Maruo, Y1
Yamaguchi, H1
Kosugi, M1
Irie, Y1
Hazama, Y1
Yasuda, T1
Peng, L1
Liu, S1
Xie, W1
Fang, X2
Xia, T1
Gu, X1
Abu-Farha, M1
Hofmann, S1
Ali, H1
Triggle, CR1
Marei, I1
Ye, K1
Ding, H1
Anderson, TJ1
Hollenberg, MD1
Hill, MA1
Shestakova, MV2
Vikulova, OK2
Elfimova, AR1
Deviatkin, AA1
Dedov, II2
Mokrysheva, NG1
Han, K1
Fyles, A1
Shek, T1
Croke, J1
Dhani, N1
D'Souza, D1
Lee, TY1
Chaudary, N1
Bruce, J1
Pintilie, M1
Cairns, R1
Vines, D1
Pakbaz, S1
Jaffray, D1
Metser, U1
Rouzbahman, M1
Milosevic, M1
Koritzinsky, M1
Bramante, CT6
Huling, JD2
Tignanelli, CJ3
Buse, JB5
Liebovitz, DM2
Nicklas, JM2
Cohen, K2
Puskarich, MA2
Belani, HK2
Proper, JL2
Siegel, LK2
Klatt, NR2
Odde, DJ2
Luke, DG1
Anderson, B1
Karger, AB2
Ingraham, NE2
Hartman, KM2
Rao, V1
Hagen, AA1
Patel, B2
Fenno, SL3
Avula, N1
Reddy, NV1
Erickson, SM3
Lindberg, S1
Fricton, R1
Lee, S1
Zaman, A4
Saveraid, HG1
Tordsen, WJ1
Pullen, MF1
Biros, M1
Sherwood, NE2
Thompson, JL2
Boulware, DR4
Murray, TA3
Morrison, FJ1
Su, M1
Turchin, A1
Ouchi, D1
Vilaplana-Carnerero, C1
de Dios, V1
Giner-Soriano, M1
Morros, R1
Dicks, HN1
Naidoo, K1
Greene, E1
MacIver, NJ1
Zhan, K1
Weng, L1
Qi, L1
Wang, L2
Lin, H1
Jia, H1
Ma, X2
Chan, LE3
Casiraghi, E3
Laraway, B3
Coleman, B3
Blau, H3
Harris, NL3
Wilkins, K3
Antony, B3
Gargano, M3
Valentini, G3
Sahner, D3
Haendel, M3
Robinson, PN3
Bramante, C3
Reese, J3
Miao, E3
Zhang, K4
Lin, J3
Yoo, D3
George, CJ3
Naseri, A2
Sanaie, S2
Hamzehzadeh, S2
Seyedi-Sahebari, S2
Hosseini, MS2
Gholipour-Khalili, E2
Rezazadeh-Gavgani, E4
Majidazar, R2
Seraji, P2
Daneshvar, S2
Shukla, AK2
Misra, S2
Petakh, P3
Griga, V1
Mohammed, IB1
Loshak, K1
Poliak, I1
Kamyshnyiy, A1
Pedrosa, AR1
Martins, DC1
Rizzo, M1
Silva-Nunes, J1
Nassar, M1
Abosheaishaa, H1
Singh, AK2
Misra, A1
Bloomgarden, Z1
Kostev, K1
Ma, Z1
Krishnamurthy, M1
Kobyliak, N1
Kamyshnyi, A2
Hernández-Velázquez, ED1
Alba-Betancourt, C1
Alonso-Castro, ÁJ1
Ortiz-Alvarado, R1
López, JA1
Meza-Carmen, V1
Solorio-Alvarado, CR1
Sandhu, HS1
Lambert, J1
Steckler, Z1
Park, L1
Stromberg, A1
Ramirez, J1
Yang, CJ1
Shimizu, R1
Matsuzaki, T1
Oka, R1
Sonoyama, T1
Fukuhara, T1
Kuwata, A1
Matsuo, Y1
Kubota, R1
Li, D3
Zhao, A1
Zhu, J3
Wang, C4
Shen, J4
Zheng, Z1
Pan, F1
Liu, Z3
Chen, Q2
Yang, Y2
Foretz, M1
Guigas, B1
Viollet, B1
Yen, FS1
Wang, SI1
Lin, SY1
Wei, JC1
Oksenych, V1
Wise, J1
Obiri-Yeboah, D1
Bena, J1
Alwakeel, M1
Buehler, L1
Makin, V1
Zhou, K1
Pantalone, KM1
Lansang, MC1
Anderson, BJ1
Pullen, M1
Wirtz, EL1
Lindberg, SM1
Beckman, KB1
Rose, MR1
Mehta, T1
Griffiths, G1
Bhat, NS1
Barzilai, N2
Kuchel, G1
Bartley, JM2
Justice, JN2
Taheri, R1
Shahrokhi, SZ1
Amjadi, Z1
Kazerouni, F1
Garrib, A1
Kivuyo, S1
Bates, K1
Ramaiya, K1
Wang, D1
Majaliwa, E1
Simbauranga, R1
Charles, G1
van Widenfelt, E1
Luo, H1
Alam, U1
Nyirenda, MJ1
Jaffar, S1
Mfinanga, S1
Petrelli, F1
Grappasonni, I1
Nguyen, CTT1
Tesauro, M1
Pantanetti, P1
Xhafa, S1
Cangelosi, G1
Wang, Y4
Yao, P1
Li, K1
Qin, S1
Miguel, V1
Rey-Serra, C1
Tituaña, J1
Sirera, B1
Alcalde-Estévez, E1
Herrero, JI1
Ranz, I1
Fernández, L1
Castillo, C1
Sevilla, L1
Nagai, J1
Reimer, KC1
Jansen, J1
Kramann, R1
Costa, IG1
Castro, A1
Sancho, D1
Rodríguez González-Moro, JM1
Lamas, S1
Zhao, X1
Jiang, Y2
Zhao, Y3
Xi, H1
Liu, C4
Qu, F1
Feng, X2
El-Arabey, AA1
Abdalla, M1
Orioli, L1
Hermans, MP1
Thissen, JP1
Maiter, D1
Vandeleene, B1
Yombi, JC1
Menendez, JA1
Koufakis, T1
Metallidis, S1
Zebekakis, P1
Ajjan, RA1
Kotsa, K1
Montastruc, JL1
Toutain, PL1
Chee, YJ1
Tan, SK1
Yeoh, E1
Esam, Z1
Fysekidis, M1
Cohen, R1
Alonso, DF1
Farina, HG1
Scheen, AJ2
Cheng, X2
Liu, YM1
Li, H7
Lei, F1
Qin, JJ1
Chen, Z2
Deng, KQ1
Lin, L1
Chen, MM1
Song, X1
Xia, M1
Huang, X2
Liu, W1
Cai, J1
Zhang, XJ1
Zhou, F1
Zhang, P2
Xu, Q1
Yang, J1
Ye, P1
Mao, W1
Xia, J1
Zhang, BH1
Guo, J2
Zhu, L1
Lu, Z2
Yuan, Y1
Wei, X1
She, ZG1
Ji, YX1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X10
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B2
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W2
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y2
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y4
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J6
Zhang, E1
Zhang, J4
Li, Y5
Xue, F1
Deng, L1
Liu, L3
Yan, Z2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Ren, Y1
Li, P2
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Zhou, X3
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Zhang, L2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X5
Lee, DF1
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y5
Wu, X1
Lu, J2
Li, M1
Li, W3
Wu, W1
Du, F1
Ji, H1
Yang, X2
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y3
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liang, C1
Yang, H2
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Gao, F1
Qi, Y1
Lu, H1
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C2
Chen, W4
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Tan, H1
Maji, TK1
J R, A1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X2
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X2
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Pan, W1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Nabi, M1
Li, F2
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Katsiki, N1
Ferrannini, E1
Gubbi, S1
Kulkarni, AS1
Kuchel, GA1
Liu, T1
Zhong, W1
Liu, R1
Zhou, H1
Zhang, W1
Guo, H1
Qiu, L1
Zhang, C1
Deng, Q1
Leng, Q1
Bain, A1
Kavanagh, S1
Merchant, HA1
Hadi, MA1
Willyard, C1
Pan, Y1
Han, R1
Do, JY1
Kim, SW1
Park, JW1
Cho, KH1
Kang, SH1
Pérez-Belmonte, LM1
Torres-Peña, JD1
López-Carmona, MD1
Ayala-Gutiérrez, MM1
Fuentes-Jiménez, F1
Jorge Huerta, L1
Muñoz, JA1
Rubio-Rivas, M1
Madrazo, M1
Garcia, MG1
Montes, BV1
Sola, JF1
Ena, J1
Ferrer, RG1
Pérez, CM1
Ripper, CJ1
Lecumberri, JJN1
Acedo, IEA1
Canteli, SP1
Cosío, SF1
Martínez, FA1
Rodríguez, BC1
Pérez-Martínez, P1
Ramos-Rincón, JM1
Gómez-Huelgas, R1
Sosibo, AM1
Khathi, A1
Lally, MA1
Tsoukas, P1
Halladay, CW1
O'Neill, E1
Gravenstein, S1
Rudolph, JL1
Couselo-Seijas, M1
Almengló, C1
M Agra-Bermejo, R1
Luis Fernandez, Á1
Alvarez, E1
R González-Juanatey, J1
Eiras, S1
Hadjadj, S1
Goronflot, T1
Pichelin, M1
Allix, I1
Amadou, C1
Bourron, O1
Duriez, T1
Gautier, JF1
Dutour, A1
Gonfroy, C1
Gouet, D1
Joubert, M1
Julier, I1
Larger, E1
Marchand, L1
Marre, M1
Meyer, L1
Olivier, F1
Prevost, G1
Quiniou, P1
Raffaitin-Cardin, C1
Roussel, R1
Saulnier, PJ1
Seret-Begue, D1
Thivolet, C1
Vatier, C1
Desailloud, R1
Wargny, M1
Gourdy, P1
Uddin, MA1
Akhter, MS1
Kubra, KT1
Siejka, A1
Barabutis, N1
Jiang, N1
Yin, X1
Tan, X1
Tian, M1
Gong, Y2
Tan, KCB1
Isakov, MА1
Damiano, S1
Sozio, C1
La Rosa, G1
Santillo, M1
Tanner, JE1
Alfieri, C1
Marin, T1
Gongol, B1
Yuan, JX1
Shyy, JY1
Crouse, AB1
Grimes, T1
Might, M1
Ovalle, F1
Shalev, A1
Marmor, S1
Hovertsen, S1
Gronski, J1
McNeil, C1
Feng, R1
Guzman, G1
Abdelwahab, N1
King, S1
Tamariz, L1
Meehan, T1
Pendleton, KM1
Benson, B1
Vojta, D1
Cooper, JM1
Gokhale, K1
Acosta-Mena, D1
Dhalla, S1
Byne, N1
Chandan, JS1
Anand, A1
Okoth, K1
Bangash, MN1
Jackson, T1
Zemedikun, D1
Taverner, T1
Hanif, W1
Ghosh, S1
Narendran, P1
Toulis, KA1
Tahrani, AA1
Surenthirakumaran, R1
Adderley, NJ1
Haroon, S1
Khunti, K1
Sainsbury, C1
Thomas, GN1
Nirantharakumar, K1
Singh, Y1
Gupta, G1
Anand, K1
Kumar Jha, N1
Thangavelu, L1
Kumar Chellappan, D1
Dua, K1
Oh, TK1
Song, IA1
Mbara, KC1
Mofo Mato, PE1
Driver, C1
Nzuza, S1
Mkhombo, NT1
Gcwensa, SK1
Mcobothi, EN1
Owira, PM1
Paquot, N1
Xin, S1
Li, L1
Duan, P1
Samuel, SM2
Varghese, E2
Büsselberg, D2
Kaneto, H1
Kimura, T1
Obata, A1
Shimoda, M1
Kaku, K1
Zangiabadian, M1
Nejadghaderi, SA1
Zahmatkesh, MM1
Hajikhani, B1
Mirsaeidi, M1
Nasiri, MJ1
Prattichizzo, F1
Sabbatinelli, J1
de Candia, P1
Olivieri, F1
Ceriello, A1
Xian, H1
Rundberg Nilsson, A1
Gatchalian, R1
Crother, TR1
Tourtellotte, WG1
Aleman-Muench, GR1
Lewis, G1
Kang, S1
Luevanos, M1
Trudler, D1
Lipton, SA1
Soroosh, P1
Teijaro, J1
de la Torre, JC1
Arditi, M1
Karin, M1
Sanchez-Lopez, E1
Liskova, A1
Kubatka, P1
Bielka, W1
Przezak, A1
Pawlik, A1
Yang, W1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, Acute Respiratory Viral Infections, and Developing Treatment Protocols[NCT05862883]Phase 2301 participants (Actual)Interventional2021-06-01Completed
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)[NCT04510194]Phase 31,323 participants (Actual)Interventional2021-01-01Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Count of Participants Who Died

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group0
Treatment Arm - Placebo Group0
Treatment Arm - Ivermectin Only Group0
Treatment Arm - Fluvoxamine Only Group0
Treatment Arm - Metformin and Fluvoxamine Group0
Treatment Arm - Metformin and Ivermectin Group1

Count of Participants With ED Visit, Hospitalization or Death

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group27
Treatment Arm - Placebo Group48
Treatment Arm - Ivermectin Only Group16
Treatment Arm - Fluvoxamine Only Group15
Treatment Arm - Metformin and Fluvoxamine Group18
Treatment Arm - Metformin and Ivermectin Group23

Count of Participants With Hospitalization or Death

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group8
Treatment Arm - Placebo Group18
Treatment Arm - Ivermectin Only Group5
Treatment Arm - Fluvoxamine Only Group5
Treatment Arm - Metformin and Fluvoxamine Group6
Treatment Arm - Metformin and Ivermectin Group4

Count of Participants With Hypoxia Only

(NCT04510194)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm - Metformin Only Group147
Treatment Arm - Placebo Group158
Treatment Arm - Ivermectin Only Group88
Treatment Arm - Fluvoxamine Only Group73
Treatment Arm - Metformin and Fluvoxamine Group71
Treatment Arm - Metformin and Ivermectin Group96

Reviews

38 reviews available for metformin and 2019 Novel Coronavirus Disease

ArticleYear
Metformin - a new approach.
    Pediatric endocrinology, diabetes, and metabolism, 2021, Volume: 27, Issue:2

    Topics: COVID-19; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Pregnancy; SARS

2021
Possible Involvement of Adipose Tissue in Patients With Older Age, Obesity, and Diabetes With SARS-CoV-2 Infection (COVID-19) via GRP78 (BIP/HSPA5): Significance of Hyperinsulinemia Management in COVID-19.
    Diabetes, 2021, Volume: 70, Issue:12

    Topics: Adipose Tissue; Adrenergic beta-3 Receptor Agonists; Aged; Aging; Angiotensin-Converting Enzyme 2; A

2021
Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 144

    Topics: COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus; Humans; Hypoglycemic Agents; Immunity, Cellula

2021
Diabetes mellitus and COVID-19: review of a lethal interaction from the cellular and molecular level to the bedside.
    Expert review of endocrinology & metabolism, 2022, Volume: 17, Issue:1

    Topics: COVID-19; Diabetes Mellitus; Humans; Metformin; Obesity; SARS-CoV-2

2022
Antidiabetic Drugs and their Potential Use in COVID-19: A Mechanistic Approach.
    Endocrine, metabolic & immune disorders drug targets, 2023, Volume: 23, Issue:3

    Topics: Antiviral Agents; COVID-19; Humans; Hypoglycemic Agents; Metformin; SARS-CoV-2

2023
Protection by metformin against severe Covid-19: An in-depth mechanistic analysis.
    Diabetes & metabolism, 2022, Volume: 48, Issue:4

    Topics: COVID-19; Diabetes Mellitus, Type 2; Humans; Metformin; Microcirculation; SARS-CoV-2

2022
Repurposing Metformin for Vascular Disease.
    Current medicinal chemistry, 2023, Volume: 30, Issue:35

    Topics: Aging; Animals; COVID-19; Drug Repositioning; Endothelial Cells; Exercise; Humans; Metformin; Vascul

2023
Targeting T cell (oxidative) metabolism to improve immunity to viral infection in the context of obesity.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Animals; COVID-19; Glucose; Humans; Metformin; Mice; Obesity; Oxidative Stress; Pandemics; SARS-CoV-

2022
Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    The Annals of pharmacotherapy, 2023, Volume: 57, Issue:7

    Topics: COVID-19; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Rec

2023
Metformin: new applications for an old drug.
    Journal of basic and clinical physiology and pharmacology, 2023, Mar-01, Volume: 34, Issue:2

    Topics: Cardiovascular Diseases; COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Off-La

2023
Metformin: new applications for an old drug.
    Journal of basic and clinical physiology and pharmacology, 2023, Mar-01, Volume: 34, Issue:2

    Topics: Cardiovascular Diseases; COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Off-La

2023
Metformin: new applications for an old drug.
    Journal of basic and clinical physiology and pharmacology, 2023, Mar-01, Volume: 34, Issue:2

    Topics: Cardiovascular Diseases; COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Off-La

2023
Metformin: new applications for an old drug.
    Journal of basic and clinical physiology and pharmacology, 2023, Mar-01, Volume: 34, Issue:2

    Topics: Cardiovascular Diseases; COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Off-La

2023
Metformin in SARS-CoV-2 infection: A hidden path - from altered inflammation to reduced mortality. A review from the literature.
    Journal of diabetes and its complications, 2023, Volume: 37, Issue:2

    Topics: COVID-19; Diabetes Mellitus, Type 2; Humans; Inflammation; Metformin; SARS-CoV-2

2023
Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis.
    Journal of diabetes, 2023, Volume: 15, Issue:2

    Topics: COVID-19; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Rec

2023
Is metformin use associated with low mortality in patients with type 2 diabetes mellitus hospitalized for COVID-19? a multivariable and propensity score-adjusted meta-analysis.
    PloS one, 2023, Volume: 18, Issue:2

    Topics: COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Propensity Score; Retro

2023
Metformin, a biological and synthetic overview.
    Bioorganic & medicinal chemistry letters, 2023, 04-15, Volume: 86

    Topics: Blood Glucose; COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin

2023
Metformin: update on mechanisms of action and repurposing potential.
    Nature reviews. Endocrinology, 2023, Volume: 19, Issue:8

    Topics: COVID-19; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Metformin

2023
Metformin for Treatment of Acute COVID-19: Systematic Review of Clinical Trial Data Against SARS-CoV-2.
    Diabetes care, 2023, 07-01, Volume: 46, Issue:7

    Topics: Adult; Bias; COVID-19; COVID-19 Drug Treatment; Humans; Metformin; SARS-CoV-2

2023
Metformin and Covid-19: a systematic review of systematic reviews with meta-analysis.
    Acta bio-medica : Atenei Parmensis, 2023, 08-30, Volume: 94, Issue:S3

    Topics: COVID-19; Databases, Factual; Humans; Metformin; SARS-CoV-2; Systematic Reviews as Topic

2023
GDF-15 (a biomarker for metformin) and the risk of COVID-19: A two-sample Mendelian randomization study.
    Medicine, 2023, Sep-29, Volume: 102, Issue:39

    Topics: Biomarkers; COVID-19; Genome-Wide Association Study; Growth Differentiation Factor 15; Humans; Mende

2023
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2020, Volume: 39, Issue:7

    Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Antimalarials; Antiviral Agents; Basal Me

2020
COVID-19 in diabetic patients: Related risks and specifics of management.
    Annales d'endocrinologie, 2020, Volume: 81, Issue:2-3

    Topics: Acidosis, Lactic; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Critical Illness;

2020
Dissecting the interaction between COVID-19 and diabetes mellitus.
    Journal of diabetes investigation, 2020, Volume: 11, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID-

2020
Metformin and COVID-19: From cellular mechanisms to reduced mortality.
    Diabetes & metabolism, 2020, Volume: 46, Issue:6

    Topics: Aged; Comorbidity; COVID-19; Diabetes Mellitus, Type 2; Hospitalization; Humans; Hypoglycemic Agents

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
    Journal of diabetes and its complications, 2020, Volume: 34, Issue:12

    Topics: Anti-Inflammatory Agents; Comorbidity; COVID-19; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV

2020
A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin.
    GeroScience, 2021, Volume: 43, Issue:3

    Topics: Aged; Communicable Diseases; COVID-19; Humans; Metformin; Multicenter Studies as Topic; RNA, Viral;

2021
Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis.
    Journal of medical virology, 2021, Volume: 93, Issue:2

    Topics: Cohort Studies; COVID-19; Diabetes Mellitus, Type 2; Humans; Metformin; Observational Studies as Top

2021
Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.
    Frontiers in immunology, 2020, Volume: 11

    Topics: Animals; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen

2020
Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients.
    Expert opinion on pharmacotherapy, 2021, Volume: 22, Issue:2

    Topics: Adrenal Cortex Hormones; Blood Glucose; Comorbidity; COVID-19; Deprescriptions; Diabetes Mellitus, T

2021
NOX-Dependent Signaling Dysregulation in Severe COVID-19: Clues to Effective Treatments.
    Frontiers in cellular and infection microbiology, 2020, Volume: 10

    Topics: Angiotensin-Converting Enzyme 2; Cardiovascular Diseases; Comorbidity; COVID-19; COVID-19 Drug Treat

2020
The Fatty Acid Lipid Metabolism Nexus in COVID-19.
    Viruses, 2021, Jan-11, Volume: 13, Issue:1

    Topics: AMP-Activated Protein Kinases; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Digestive System

2021
Molecular exploration of combinational therapy of orlistat with metformin prevents the COVID-19 consequences in obese diabetic patients.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:2

    Topics: Anti-Obesity Agents; COVID-19; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hypoglycemic Ag

2021
Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications.
    European journal of pharmacology, 2021, May-05, Volume: 898

    Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cardiovascular Diseases; COVID-19; COVID-19 D

2021
Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role.
    Trends in microbiology, 2021, Volume: 29, Issue:10

    Topics: Animals; Blood Glucose; COVID-19; Diabetes Mellitus; Drug Repositioning; Humans; Hypoglycemic Agents

2021
Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History.
    International journal of molecular sciences, 2021, Mar-05, Volume: 22, Issue:5

    Topics: Autophagy; COVID-19; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Insulin-Secreti

2021
The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: COVID-19; COVID-19 Drug Treatment; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic A

2021
Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing.
    PLoS pathogens, 2021, Volume: 17, Issue:6

    Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Diabetes Com

2021
Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection.
    International journal of molecular sciences, 2021, Jul-16, Volume: 22, Issue:14

    Topics: Angiotensin-Converting Enzyme Inhibitors; COVID-19; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase

2021
The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus.
    Diabetes research and clinical practice, 2021, Volume: 178

    Topics: COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin

2021

Trials

6 trials available for metformin and 2019 Novel Coronavirus Disease

ArticleYear
Protocol for the Metformin Aneurysm Trial (MAT): a placebo-controlled randomised trial testing whether metformin reduces the risk of serious complications of abdominal aortic aneurysm.
    Trials, 2021, Dec-27, Volume: 22, Issue:1

    Topics: Aortic Aneurysm, Abdominal; Australia; COVID-19; Humans; Metformin; Pandemics; Prospective Studies;

2021
A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 12-15, Volume: 28, Issue:24

    Topics: COVID-19; Female; Humans; Hypoxia; Metformin; Nitroimidazoles; Pandemics; Positron Emission Tomograp

2022
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
    The New England journal of medicine, 2022, 08-18, Volume: 387, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Double-Blind M

2022
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
    The Lancet. Infectious diseases, 2023, Volume: 23, Issue:10

    Topics: Adult; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Female; Fluvoxamine; Humans; Incidenc

2023
Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial.
    Diabetologia, 2023, Volume: 66, Issue:10

    Topics: Adolescent; Adult; Blood Glucose; COVID-19; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting;

2023
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021

Other Studies

69 other studies available for metformin and 2019 Novel Coronavirus Disease

ArticleYear
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Nature, 2020, Volume: 583, Issue:7816

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In

2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Nature, 2020, Volume: 583, Issue:7816

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In

2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Nature, 2020, Volume: 583, Issue:7816

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In

2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Nature, 2020, Volume: 583, Issue:7816

    Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In

2020
Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States.
    Scientific reports, 2021, 09-09, Volume: 11, Issue:1

    Topics: Aged; Aging; COVID-19; COVID-19 Drug Treatment; Critical Care; Diabetes Complications; Diabetes Mell

2021
Inpatient use of metformin and acarbose is associated with reduced mortality of COVID-19 patients with type 2 diabetes mellitus.
    Endocrinology, diabetes & metabolism, 2022, Volume: 5, Issue:1

    Topics: Acarbose; COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inpatients; Metformin; R

2022
Preliminary Evidence for IL-10-Induced ACE2 mRNA Expression in Lung-Derived and Endothelial Cells: Implications for SARS-Cov-2 ARDS Pathogenesis.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Cell Line; COVID-19; Host-Pathogen Intera

2021
Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong.
    BMJ open, 2021, 10-20, Volume: 11, Issue:10

    Topics: Aged; COVID-19; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucose; Hong

2021
Metformin Suppresses Monocyte Immunometabolic Activation by SARS-CoV-2 Spike Protein Subunit 1.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Cells, Cultured; COVID-19; Humans; Metformin; Monocytes; SARS-CoV-2; Spike Glycoprotein, Coronavirus

2021
Metformin-associated lactic acidosis and acute kidney injury in the era of COVID-19.
    Frontiers in bioscience (Scholar edition), 2021, 12-03, Volume: 13, Issue:2

    Topics: Acidosis, Lactic; Acute Kidney Injury; COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Age

2021
Metainflammation in COVID-19.
    Endocrine, metabolic & immune disorders drug targets, 2022, Volume: 22, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme 2; COVID-19; Dipeptidyl Peptidase 4; Eplerenone; Female; Humans;

2022
Metformin in COVID-19: clinical trials are needed to prove its benefits.
    Irish journal of medical science, 2022, Volume: 191, Issue:6

    Topics: COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin

2022
Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: A population-based study in Lombardy.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:5

    Topics: Adult; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus; Hospitalization; Humans; Hypoglycemic A

2022
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.
    Journal of thrombosis and thrombolysis, 2022, Volume: 53, Issue:2

    Topics: COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus; Hospitalization; Humans; Hypoglycemic Agents;

2022
Response to "Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study".
    Acta diabetologica, 2022, Volume: 59, Issue:6

    Topics: Cohort Studies; COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin

2022
Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Hospital Mortality; Humans; Metformin;

2022
A comment on metformin and COVID-19 with regard to "Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: A population-based study in Lombardy".
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:9

    Topics: COVID-19; Diabetes Mellitus, Type 2; Hospitalization; Humans; Hypoglycemic Agents; Metformin; Retros

2022
Metformin-associated Lactic Acidosis with Hypoglycemia during the COVID-19 Pandemic.
    Internal medicine (Tokyo, Japan), 2022, Aug-01, Volume: 61, Issue:15

    Topics: Acidosis, Lactic; COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Ma

2022
Metformin alleviates prolonged isoflurane inhalation induced cognitive decline via reducing neuroinflammation in adult mice.
    International immunopharmacology, 2022, Volume: 109

    Topics: Anesthetics; Animals; Cognitive Dysfunction; COVID-19; Isoflurane; Metformin; Mice; Microglia; Neuro

2022
Editorial: Covid-19 and Diabetes.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: COVID-19; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin

2022
Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Aged; Coronavirus; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type 1; Diabetes Mellitus, T

2022
COVID-19 outcomes in patients taking cardioprotective medications.
    PloS one, 2022, Volume: 17, Issue:10

    Topics: Aspirin; COVID-19; COVID-19 Drug Treatment; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reduc

2022
Antidiabetic treatment and COVID-19 Outcomes: A population-based cohort study in primary health care in Catalonia during the first wave of the pandemic.
    Primary care diabetes, 2022, Volume: 16, Issue:6

    Topics: Cohort Studies; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Humans; Hypoglycemic A

2022
COVID-19 and diabetic ketoacidosis: A case series at an urban district hospital in South Africa.
    South African family practice : official journal of the South African Academy of Family Practice/Primary Care, 2022, 09-22, Volume: 64, Issue:1

    Topics: Adult; Biphasic Insulins; COVID-19; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glycat

2022
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
    Diabetes research and clinical practice, 2022, Volume: 194

    Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta

2022
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
    Diabetes research and clinical practice, 2022, Volume: 194

    Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta

2022
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
    Diabetes research and clinical practice, 2022, Volume: 194

    Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta

2022
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
    Diabetes research and clinical practice, 2022, Volume: 194

    Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta

2022
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
    Diabetes research and clinical practice, 2022, Volume: 194

    Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta

2022
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
    Diabetes research and clinical practice, 2022, Volume: 194

    Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta

2022
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
    Diabetes research and clinical practice, 2022, Volume: 194

    Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta

2022
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
    Diabetes research and clinical practice, 2022, Volume: 194

    Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta

2022
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
    Diabetes research and clinical practice, 2022, Volume: 194

    Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta

2022
Metformin use and mortality and length of stay among hospitalized patients with type 2 diabetes and COVID-19: A multiracial, multiethnic, urban observational study.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Length of

2022
Metformin use and mortality and length of stay among hospitalized patients with type 2 diabetes and COVID-19: A multiracial, multiethnic, urban observational study.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Length of

2022
Metformin use and mortality and length of stay among hospitalized patients with type 2 diabetes and COVID-19: A multiracial, multiethnic, urban observational study.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Length of

2022
Metformin use and mortality and length of stay among hospitalized patients with type 2 diabetes and COVID-19: A multiracial, multiethnic, urban observational study.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Length of

2022
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
    The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24

    Topics: COVID-19; Fluvoxamine; Humans; Ivermectin; Metformin

2022
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
    The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24

    Topics: COVID-19; Fluvoxamine; Humans; Ivermectin; Metformin

2022
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
    The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24

    Topics: COVID-19; Fluvoxamine; Humans; Ivermectin; Metformin

2022
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
    The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24

    Topics: COVID-19; Fluvoxamine; Humans; Ivermectin; Metformin

2022
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. Reply.
    The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24

    Topics: COVID-19; Fluvoxamine; Humans; Ivermectin; Metformin

2022
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. Reply.
    The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24

    Topics: COVID-19; Fluvoxamine; Humans; Ivermectin; Metformin

2022
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. Reply.
    The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24

    Topics: COVID-19; Fluvoxamine; Humans; Ivermectin; Metformin

2022
Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. Reply.
    The New England journal of medicine, 2022, 12-15, Volume: 387, Issue:24

    Topics: COVID-19; Fluvoxamine; Humans; Ivermectin; Metformin

2022
Effects of Metformin, Insulin on Hematological Parameters of COVID-19 Patients with Type 2 Diabetes.
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2022, Volume: 76, Issue:5

    Topics: COVID-19; Diabetes Mellitus, Type 2; Humans; Insulin; Metformin; Retrospective Studies; SARS-CoV-2

2022
Metformin, cancer, COVID-19, and longevity.
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:3

    Topics: COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Longevity; Metformin; Neoplasms

2023
Gut microbiota in patients with COVID-19 and type 2 diabetes: A culture-based method.
    Frontiers in cellular and infection microbiology, 2023, Volume: 13

    Topics: Bifidobacterium; COVID-19; Diabetes Mellitus, Type 2; Enterococcus; Gastrointestinal Microbiome; Hum

2023
Outpatient medications associated with protection from COVID-19 hospitalization.
    PloS one, 2023, Volume: 18, Issue:3

    Topics: COVID-19; Hospitalization; Humans; Metformin; Middle Aged; Outpatients; Pandemics; Retrospective Stu

2023
Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
    Journal of clinical pharmacology, 2023, Volume: 63, Issue:8

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily

2023
Inhaled Lipid Nanoparticles Alleviate Established Pulmonary Fibrosis.
    Small (Weinheim an der Bergstrasse, Germany), 2023, Volume: 19, Issue:30

    Topics: COVID-19; Fibrosis; Humans; Liposomes; Lung; Metformin; Pulmonary Fibrosis; SARS-CoV-2

2023
Metformin use before COVID-19 vaccination and the risks of COVID-19 incidence, medical utilization, and all-cause mortality in patients with type 2 diabetes mellitus.
    Diabetes research and clinical practice, 2023, Volume: 200

    Topics: COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin; Retrospectiv

2023
The F/B ratio as a biomarker for inflammation in COVID-19 and T2D: Impact of metformin.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 163

    Topics: Bacteroidetes; Biomarkers; C-Reactive Protein; COVID-19; Diabetes Mellitus, Type 2; Firmicutes; Huma

2023
COVID-19 update: Metformin to prevent long COVID?
    The Medical letter on drugs and therapeutics, 2023, 05-29, Volume: 65, Issue:1677

    Topics: COVID-19; Humans; Hypoglycemic Agents; Ivermectin; Metformin; Post-Acute COVID-19 Syndrome; SARS-CoV

2023
Covid-19: Metformin reduces the risk of developing long term symptoms by 40%, study finds.
    BMJ (Clinical research ed.), 2023, 06-08, Volume: 381

    Topics: COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin

2023
Association of Metformin, Dipeptidyl Dipeptidase-4 Inhibitors, and Insulin with Coronavirus Disease 2019-Related Hospital Outcomes in Patients with Type 2 Diabetes.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2023, Volume: 29, Issue:9

    Topics: COVID-19; Diabetes Mellitus, Type 2; Dipeptidases; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemo

2023
Investigating the impact of metformin on severity of COVID-19 in patients with Type 2 diabetes mellitus: Focusing on laboratory findings.
    Endocrinology, diabetes & metabolism, 2023, Volume: 6, Issue:5

    Topics: COVID-19; Diabetes Mellitus, Type 2; Humans; Metformin; SARS-CoV-2

2023
Enhanced fatty acid oxidation through metformin and baicalin as therapy for COVID-19 and associated inflammatory states in lung and kidney.
    Redox biology, 2023, Volume: 68

    Topics: AMP-Activated Protein Kinases; Animals; COVID-19; Fatty Acids; Fibrosis; Humans; Inflammation; Kidne

2023
Metformin and COVID-19: A novel deal of an old drug.
    Journal of medical virology, 2020, Volume: 92, Issue:11

    Topics: Adjuvants, Pharmaceutic; Age Factors; China; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, T

2020
Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.
    Aging, 2020, 05-27, Volume: 12, Issue:10

    Topics: Aged; Betacoronavirus; Calcium Release Activated Calcium Channels; Coronavirus Infections; COVID-19;

2020
Metformin use amid coronavirus disease 2019 pandemic.
    Journal of medical virology, 2020, Volume: 92, Issue:11

    Topics: COVID-19; Humans; Metformin; Pandemics; Pharmaceutical Preparations; SARS-CoV-2

2020
Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?
    Journal of diabetes science and technology, 2020, Volume: 14, Issue:4

    Topics: Betacoronavirus; Cardiovascular Diseases; Coronavirus Infections; COVID-19; Cytokines; Diabetes Mell

2020
A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study.
    Drug safety, 2020, Volume: 43, Issue:7

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Betacoronavirus; Coronavirus Infections; COVID-19; D

2020
A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19.
    Diabetes research and clinical practice, 2020, Volume: 167

    Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Metformin; Pande

2020
More Studies are Needed on the Link between Metformin and Decreased Mortality in Diabetic COVID-19 Patients.
    The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:3

    Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Diabetes Mellitus; Humans; Metformin; Pandemics;

2020
Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:3

    Topics: Anticholesteremic Agents; Antineoplastic Agents; Antiparasitic Agents; Antiviral Agents; Betacoronav

2020
Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes.
    Cell metabolism, 2020, 10-06, Volume: 32, Issue:4

    Topics: Acidosis; Acidosis, Lactic; Aged; China; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type 2

2020
Risk of Metformin in Patients With Type 2 Diabetes With COVID-19: A Preliminary Retrospective Report.
    Clinical and translational science, 2020, Volume: 13, Issue:6

    Topics: Aged; Angiotensin-Converting Enzyme 2; Blood Glucose; COVID-19; Diabetes Mellitus, Type 2; Female; H

2020
How anti-ageing drugs could boost COVID vaccines in older people.
    Nature, 2020, Volume: 586, Issue:7829

    Topics: Adult; Aged; Aging; Animals; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Va

2020
[Metformin: one of the possible options to reduce the mortality of severe coronavirus disease 2019?]
    Zhonghua wei zhong bing ji jiu yi xue, 2020, Volume: 32, Issue:9

    Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Endothelial Cells; Metfo

2020
Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19?
    Diabetes & metabolism, 2021, Volume: 47, Issue:4

    Topics: Acute Kidney Injury; Adult; Aged; Cardiotonic Agents; COVID-19; Diabetes Mellitus, Type 2; Extracorp

2021
Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
    BMC medicine, 2020, 11-16, Volume: 18, Issue:1

    Topics: Aged; Aged, 80 and over; Betacoronavirus; Cohort Studies; Coronavirus Infections; COVID-19; Diabetes

2020
Pre-diabetes and COVID-19, could we be missing the silent killer?
    Experimental biology and medicine (Maywood, N.J.), 2021, Volume: 246, Issue:4

    Topics: Blood Glucose; Comorbidity; COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metfor

2021
Metformin is Associated with Decreased 30-Day Mortality Among Nursing Home Residents Infected with SARS-CoV2.
    Journal of the American Medical Directors Association, 2021, Volume: 22, Issue:1

    Topics: Aged; COVID-19; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nursing Homes; Pr

2021
Higher ACE2 expression levels in epicardial cells than subcutaneous stromal cells from patients with cardiovascular disease: Diabetes and obesity as possible enhancer.
    European journal of clinical investigation, 2021, Volume: 51, Issue:5

    Topics: ADAM17 Protein; Adipogenesis; Adipose Tissue; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme

2021
Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19.
    Diabetes & metabolism, 2021, Volume: 47, Issue:5

    Topics: Aged; Aged, 80 and over; COVID-19; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypog

2021
Metformin in acute respiratory distress syndrome: An opinion.
    Experimental gerontology, 2021, Volume: 145

    Topics: Animals; Cattle; COVID-19; Endothelial Cells; Humans; Lung; Metformin; Respiratory Distress Syndrome

2021
Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study.
    Diabetes research and clinical practice, 2021, Volume: 173

    Topics: Aged; China; Cohort Studies; COVID-19; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; M

2021
Is metformin a miracle or a menace in COVID-19 patients with type 2 diabetes?
    Journal of diabetes investigation, 2021, Volume: 12, Issue:4

    Topics: Acidosis; COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin; SA

2021
[Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the russian diabetes registry].
    Problemy endokrinologii, 2020, 08-04, Volume: 66, Issue:1

    Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors;

2020
Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2020, Volume: 26, Issue:10

    Topics: China; COVID-19; Diabetes Mellitus, Type 2; Hospitalization; Humans; Metformin; Retrospective Studie

2020
Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes.
    Frontiers in endocrinology, 2020, Volume: 11

    Topics: Aged; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus; Ethnicity; Female; Follow-Up Studies; Ho

2020
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis.
    The lancet. Healthy longevity, 2021, Volume: 2, Issue:1

    Topics: Cohort Studies; COVID-19; Diabetes Mellitus, Type 2; Female; Humans; Male; Metformin; Obesity; Retro

2021
Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes.
    The Journal of clinical endocrinology and metabolism, 2021, 04-23, Volume: 106, Issue:5

    Topics: Aged; Cohort Studies; COVID-19; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Kapl

2021
Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study.
    Acta diabetologica, 2021, Volume: 58, Issue:6

    Topics: Adult; Aged; Cohort Studies; COVID-19; Databases, Factual; Diabetes Mellitus, Type 2; Hospital Morta

2021
[Continuing or stopping metformin in patients with type 2 diabetes exposed to SARS-CoV-2 ?]
    Revue medicale de Liege, 2021, Volume: 76, Issue:3

    Topics: Acidosis, Lactic; COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; SARS-

2021
Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study.
    Life sciences, 2021, Jun-15, Volume: 275

    Topics: Adult; Blood Glucose; China; COVID-19; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; H

2021
Tackling the pillars of ageing to fight COVID-19.
    The lancet. Healthy longevity, 2021, Volume: 2, Issue:4

    Topics: Aging; Cohort Studies; COVID-19; Humans; Metformin; Retrospective Studies

2021
Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation.
    Immunity, 2021, 07-13, Volume: 54, Issue:7

    Topics: Adenosine Triphosphate; Animals; COVID-19; Cytokines; DNA, Mitochondrial; Humans; Inflammasomes; Int

2021